The MOVES-PD study, a randomized, multicenter, double-blind, placebo-controlled trial, was conducted to evaluate the ability of the glucosylceramide synthase inhibitor Venglustat (GZ/SAR402671) to target substrate reduction in PD patients carrying GBA variants (NCT02906020). The gene discussed is UGCG; the disease is Parkinson disease.